Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SEGLENTIS

CELECOXIB; TRAMADOL HYDROCHLORIDE

Standard Dose
56MG;44MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SEGLENTIS is listed in Drugs@FDA under application 213426 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CELECOXIB; TRAMADOL HYDROCHLORIDE Form and strength TABLET;ORAL - 56MG;44MG Sponsor KOWA PHARMS Submission history Latest submission status date: 2024-11-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview SEGLENTIS is listed in Drugs@FDA under application 213426 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CELECOXIB; TRAMADOL HYDROCHLORIDE Form and strength TABLET;ORAL - 56MG;44MG Sponsor KOWA PHARMS Submission history Latest submission status date: 2024-11-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
SEGLENTIS (CELECOXIB; TRAMADOL HYDROCHLORIDE) | Drug Monograph | MedicHelpline